Atlas Trials

Relapse Multiple Myeloma

29 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Relapse Multiple Myeloma

RecordFirmDate
Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT05117008)Medical College of Wisconsin2022-07-19
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (NCT05431608)Memorial Sloan Kettering Cancer Center2022-06-20
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma (NCT05430945)Zhejiang University2022-06-20
Descartes-25 in Relapsed/Refractory Multiple Myeloma (NCT05113342)Cartesian Therapeutics2021-11-25
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab (NCT04302324)Weill Medical College of Cornell University2021-10-28
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma (NCT05243212)Sheba Medical Center2021-09-19
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma (NCT05150522)Shenzhen University General Hospital2021-07-01
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (NCT04355039)Medical College of Wisconsin2021-07-01
A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma (NCT04918511)Oncopeptides AB2021-05-27
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma (NCT04670055)Zhejiang University2021-01-01
A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy (NCT04541368)Zhejiang University2020-12-31
Multiple Myeloma Turkish Prospective Patient Registry (NCT04143932)Turkish Hematology Association2020-10-10
Carfilzomib in Combination for the Treatment of RR MM (NCT04004338)Black Sea Hematology Association2019-04-14
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma (NCT03143049)National University Hospital, Singapore2017-09-13
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib (NCT01775553)Ajai Chari2013-09-01

Track Relapse Multiple Myeloma automatically

Every clearance here is in the API, with alerts when new ones post.